Review



rnai viability assay screening  (Broad Institute Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Broad Institute Inc rnai viability assay screening
    A . BHLHE41 is an essential gene in several cancer cell types. Boxplots showing the dependency scores calculated using data from the Cancer Dependency Map project ( https://depmap.org ). <t>RNAi-based</t> <t>viability</t> assays in Ewing sarcoma ( n =10), multiple myeloma ( n = 16), non-Hodgkin lymphoma ( n = 26) and acute myeloid leukemia ( n = 22) cell lines. DEMETER2 scores were calculated using data from RNAi-based screens. The mention “all” refers to the 974 cell lines included in the projects Achilles, DRIVE and Marcotte. A DEMETER score = 0 indicates that the gene is not essential. A lower score indicates that the gene is more likely to be essential in a given cell line. The figure shows the scores for the BHLHE41 gene in the indicated samples. B. A high expression of BHLHE41 is associated with a poor survival in patients with AML and MM. The link between BHLHE41 and outcome in hematological malignancies was investigated using GenomicScape webtool ( http://www.genomicscape.com/microarray/survival.php ). High BHLHE41 expression (red) is associated with a significant poor overall survival in a cohort of newly-diagnosed cytogenetically normal AML (GSE12417—Gene expression omnibus, n =163) and a cohort of newly diagnosed MM patients (HM cohort, n =206, Array Express public database (E-MTAB372)) compared to patients with low BHLHE41 expression (blue)
    Rnai Viability Assay Screening, supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rnai+viability+assay+screening/pmc11850569-311-5-12?v=Broad+Institute+Inc
    Average 90 stars, based on 1 article reviews
    rnai viability assay screening - by Bioz Stars, 2026-07
    90/100 stars

    Images

    1) Product Images from "BHLHE41, a transcriptional repressor involved in physiological processes and tumor development"

    Article Title: BHLHE41, a transcriptional repressor involved in physiological processes and tumor development

    Journal: Cellular Oncology (Dordrecht, Netherlands)

    doi: 10.1007/s13402-024-00973-3

    A . BHLHE41 is an essential gene in several cancer cell types. Boxplots showing the dependency scores calculated using data from the Cancer Dependency Map project ( https://depmap.org ). RNAi-based viability assays in Ewing sarcoma ( n =10), multiple myeloma ( n = 16), non-Hodgkin lymphoma ( n = 26) and acute myeloid leukemia ( n = 22) cell lines. DEMETER2 scores were calculated using data from RNAi-based screens. The mention “all” refers to the 974 cell lines included in the projects Achilles, DRIVE and Marcotte. A DEMETER score = 0 indicates that the gene is not essential. A lower score indicates that the gene is more likely to be essential in a given cell line. The figure shows the scores for the BHLHE41 gene in the indicated samples. B. A high expression of BHLHE41 is associated with a poor survival in patients with AML and MM. The link between BHLHE41 and outcome in hematological malignancies was investigated using GenomicScape webtool ( http://www.genomicscape.com/microarray/survival.php ). High BHLHE41 expression (red) is associated with a significant poor overall survival in a cohort of newly-diagnosed cytogenetically normal AML (GSE12417—Gene expression omnibus, n =163) and a cohort of newly diagnosed MM patients (HM cohort, n =206, Array Express public database (E-MTAB372)) compared to patients with low BHLHE41 expression (blue)
    Figure Legend Snippet: A . BHLHE41 is an essential gene in several cancer cell types. Boxplots showing the dependency scores calculated using data from the Cancer Dependency Map project ( https://depmap.org ). RNAi-based viability assays in Ewing sarcoma ( n =10), multiple myeloma ( n = 16), non-Hodgkin lymphoma ( n = 26) and acute myeloid leukemia ( n = 22) cell lines. DEMETER2 scores were calculated using data from RNAi-based screens. The mention “all” refers to the 974 cell lines included in the projects Achilles, DRIVE and Marcotte. A DEMETER score = 0 indicates that the gene is not essential. A lower score indicates that the gene is more likely to be essential in a given cell line. The figure shows the scores for the BHLHE41 gene in the indicated samples. B. A high expression of BHLHE41 is associated with a poor survival in patients with AML and MM. The link between BHLHE41 and outcome in hematological malignancies was investigated using GenomicScape webtool ( http://www.genomicscape.com/microarray/survival.php ). High BHLHE41 expression (red) is associated with a significant poor overall survival in a cohort of newly-diagnosed cytogenetically normal AML (GSE12417—Gene expression omnibus, n =163) and a cohort of newly diagnosed MM patients (HM cohort, n =206, Array Express public database (E-MTAB372)) compared to patients with low BHLHE41 expression (blue)

    Techniques Used: Expressing, Microarray, Gene Expression



    Similar Products

    rnai viability assay screening  (Broad Institute Inc)
    90
    Broad Institute Inc rnai viability assay screening
    A . BHLHE41 is an essential gene in several cancer cell types. Boxplots showing the dependency scores calculated using data from the Cancer Dependency Map project ( https://depmap.org ). <t>RNAi-based</t> <t>viability</t> assays in Ewing sarcoma ( n =10), multiple myeloma ( n = 16), non-Hodgkin lymphoma ( n = 26) and acute myeloid leukemia ( n = 22) cell lines. DEMETER2 scores were calculated using data from RNAi-based screens. The mention “all” refers to the 974 cell lines included in the projects Achilles, DRIVE and Marcotte. A DEMETER score = 0 indicates that the gene is not essential. A lower score indicates that the gene is more likely to be essential in a given cell line. The figure shows the scores for the BHLHE41 gene in the indicated samples. B. A high expression of BHLHE41 is associated with a poor survival in patients with AML and MM. The link between BHLHE41 and outcome in hematological malignancies was investigated using GenomicScape webtool ( http://www.genomicscape.com/microarray/survival.php ). High BHLHE41 expression (red) is associated with a significant poor overall survival in a cohort of newly-diagnosed cytogenetically normal AML (GSE12417—Gene expression omnibus, n =163) and a cohort of newly diagnosed MM patients (HM cohort, n =206, Array Express public database (E-MTAB372)) compared to patients with low BHLHE41 expression (blue)
    Rnai Viability Assay Screening, supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rnai+viability+assay+screening/pmc11850569-311-5-12?v=Broad+Institute+Inc
    Average 90 stars, based on 1 article reviews
    rnai viability assay screening - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    rnai dropout viability and rescue screens  (Cellecta Inc)
    90
    Cellecta Inc rnai dropout viability and rescue screens
    A . BHLHE41 is an essential gene in several cancer cell types. Boxplots showing the dependency scores calculated using data from the Cancer Dependency Map project ( https://depmap.org ). <t>RNAi-based</t> <t>viability</t> assays in Ewing sarcoma ( n =10), multiple myeloma ( n = 16), non-Hodgkin lymphoma ( n = 26) and acute myeloid leukemia ( n = 22) cell lines. DEMETER2 scores were calculated using data from RNAi-based screens. The mention “all” refers to the 974 cell lines included in the projects Achilles, DRIVE and Marcotte. A DEMETER score = 0 indicates that the gene is not essential. A lower score indicates that the gene is more likely to be essential in a given cell line. The figure shows the scores for the BHLHE41 gene in the indicated samples. B. A high expression of BHLHE41 is associated with a poor survival in patients with AML and MM. The link between BHLHE41 and outcome in hematological malignancies was investigated using GenomicScape webtool ( http://www.genomicscape.com/microarray/survival.php ). High BHLHE41 expression (red) is associated with a significant poor overall survival in a cohort of newly-diagnosed cytogenetically normal AML (GSE12417—Gene expression omnibus, n =163) and a cohort of newly diagnosed MM patients (HM cohort, n =206, Array Express public database (E-MTAB372)) compared to patients with low BHLHE41 expression (blue)
    Rnai Dropout Viability And Rescue Screens, supplied by Cellecta Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rnai+viability+assay+screening/10__1089_slash_gen__33__8__09-64-7-0?v=Cellecta+Inc
    Average 90 stars, based on 1 article reviews
    rnai dropout viability and rescue screens - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    A . BHLHE41 is an essential gene in several cancer cell types. Boxplots showing the dependency scores calculated using data from the Cancer Dependency Map project ( https://depmap.org ). RNAi-based viability assays in Ewing sarcoma ( n =10), multiple myeloma ( n = 16), non-Hodgkin lymphoma ( n = 26) and acute myeloid leukemia ( n = 22) cell lines. DEMETER2 scores were calculated using data from RNAi-based screens. The mention “all” refers to the 974 cell lines included in the projects Achilles, DRIVE and Marcotte. A DEMETER score = 0 indicates that the gene is not essential. A lower score indicates that the gene is more likely to be essential in a given cell line. The figure shows the scores for the BHLHE41 gene in the indicated samples. B. A high expression of BHLHE41 is associated with a poor survival in patients with AML and MM. The link between BHLHE41 and outcome in hematological malignancies was investigated using GenomicScape webtool ( http://www.genomicscape.com/microarray/survival.php ). High BHLHE41 expression (red) is associated with a significant poor overall survival in a cohort of newly-diagnosed cytogenetically normal AML (GSE12417—Gene expression omnibus, n =163) and a cohort of newly diagnosed MM patients (HM cohort, n =206, Array Express public database (E-MTAB372)) compared to patients with low BHLHE41 expression (blue)

    Journal: Cellular Oncology (Dordrecht, Netherlands)

    Article Title: BHLHE41, a transcriptional repressor involved in physiological processes and tumor development

    doi: 10.1007/s13402-024-00973-3

    Figure Lengend Snippet: A . BHLHE41 is an essential gene in several cancer cell types. Boxplots showing the dependency scores calculated using data from the Cancer Dependency Map project ( https://depmap.org ). RNAi-based viability assays in Ewing sarcoma ( n =10), multiple myeloma ( n = 16), non-Hodgkin lymphoma ( n = 26) and acute myeloid leukemia ( n = 22) cell lines. DEMETER2 scores were calculated using data from RNAi-based screens. The mention “all” refers to the 974 cell lines included in the projects Achilles, DRIVE and Marcotte. A DEMETER score = 0 indicates that the gene is not essential. A lower score indicates that the gene is more likely to be essential in a given cell line. The figure shows the scores for the BHLHE41 gene in the indicated samples. B. A high expression of BHLHE41 is associated with a poor survival in patients with AML and MM. The link between BHLHE41 and outcome in hematological malignancies was investigated using GenomicScape webtool ( http://www.genomicscape.com/microarray/survival.php ). High BHLHE41 expression (red) is associated with a significant poor overall survival in a cohort of newly-diagnosed cytogenetically normal AML (GSE12417—Gene expression omnibus, n =163) and a cohort of newly diagnosed MM patients (HM cohort, n =206, Array Express public database (E-MTAB372)) compared to patients with low BHLHE41 expression (blue)

    Article Snippet: We used public datasets of RNAi viability assay screening (Dependency Map data, Broad Institute, www.depmap.org ) [ ] to determine whether BHLHE41 is an essential gene in several cancers.

    Techniques: Expressing, Microarray, Gene Expression